American Journal of Kidney Diseases
Volume 56, Issue 2 , Pages 325-337 , August 2010

Vasopressin Receptor Antagonists for the Treatment of Hyponatremia: Systematic Review and Meta-analysis

  • Benaya Rozen-Zvi, MD

      Affiliations

    • Department of Nephrology and Hypertension, Rabin Medical Center, Petah-Tikva, and the Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
    • B.R.-Z. and D.Y. contributed equally to this work.
    • Corresponding Author InformationAddress correspondence to Benaya Rozen-Zvi, MD, Nephrology and Hypertension Department, Rabin Medical Center, Beilinson Hospital, Petah-Tikva 49100, Israel
    • ,
  • Dafna Yahav, MD

      Affiliations

    • Department of Medicine E, Rabin Medical Center, Petah-Tikva, and the Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
    • B.R.-Z. and D.Y. contributed equally to this work.
    • ,
  • Mihai Gheorghiade, MD

      Affiliations

    • Northwestern University, Feinberg School of Medicine, Chicago, IL
    • ,
  • Asher Korzets, MD

      Affiliations

    • Department of Nephrology and Hypertension, Rabin Medical Center, Petah-Tikva, and the Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
    • ,
  • Leonard Leibovici, MD

      Affiliations

    • Department of Medicine E, Rabin Medical Center, Petah-Tikva, and the Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
    • ,
  • Uzi Gafter, MD, PhD

      Affiliations

    • Department of Nephrology and Hypertension, Rabin Medical Center, Petah-Tikva, and the Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

Received 6 September 2009 ,Accepted 4 January 2010.

References 

  1. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–2112
  2. Upadhyay A, Jaber BL, Madias NE. Epidemiology of hyponatremia. Semin Nephrol. 2009;29(3):227–238
  3. Wu CC, Yeung LK, Tsai WS, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol. 2006;65(1):28–33
  4. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005;111(19):2454–2460
  5. De Luca L, Klein L, Udelson JE, et al. Hyponatremia in patients with heart failure. Am J Cardiol. 2005;96(12A):19L–23L
  6. Londono MC, Guevara M, Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology. 2006;130(4):1135–1143
  7. Sica DA. Hyponatremia and heart failure—pathophysiology and implications. Congest Heart Fail. 2005;11(5):274–277
  8. Goldberg A, Hammerman H, Petcherski S, et al. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med. 2006;166(7):781–786
  9. Bhardwaj A. Neurological impact of vasopressin dysregulation and hyponatremia. Ann Neurol. 2006;59(2):229–236
  10. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119(1):e71–e78
  11. Bekheirnia MR, Schrier RW. Pathophysiology of water and sodium retention: edematous states with normal kidney function. Curr Opin Pharmacol. 2006;6(2):202–207
  12. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol. 2006;17(7):1820–1832
  13. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11 suppl 1):S1–S21
  14. Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med. 2006;119(7 suppl 1):S36–S42
  15. Gross P. Treatment of hyponatremia. Intern Med. 2008;47(10):885–891
  16. Decaux G, Mols P, Cauchi P, Delwiche F. Use of urea for treatment of water retention in hyponatraemic cirrhosis with ascites resistant to diuretics. Br Med J. 1985;290(6484):1782–1783
  17. White MG, Fetner CD. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with lithium carbonate. N Engl J Med. 1975;292(8):390–392
  18. Brunner JE, Redmond JM, Haggar AM, Kruger DF, Elias SB. Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia: a prospective magnetic resonance imaging study. Ann Neurol. 1990;27(1):61–66
  19. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371(9624):1624–1632
  20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560
  21. In:  Higgins JP,  Green S editor. Cochrane Handbook for Systematic Reviews of Interventions version 5.0.1 [updated September 2008]. The Cochrane Collaboration; 2008;www.cochrane-handbook.orgAccessed March 1, 2010
  22. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992;45(7):769–773
  23. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18(20):2693–2708
  24. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–1331
  25. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37(1):182–191
  26. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447–457
  27. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol. 2006;1(6):1154–1160
  28. Rossi J, Bayram M, Udelson JE, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care. 2007;9(2):82–86
  29. Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008;48(1):204–213
  30. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107(21):2690–2696
  31. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006;97(7):1064–1067
  32. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91(6):2145–2152
  33. Aronson D, Mueller M, Verbalis K, Krum H. Satavaptan, a vasopressin V2-receptor antagonist, in the treatment of dilutional hyponatremia [abstract]. J Am Soc Nephrol. 2007;18(abstracts issue):790A
  34. Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009;337(1):28–36
  35. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124(4):933–939
  36. Decaux G, Soupart A, Mueller M, Finta E, Alfoldi S. Long-term satavaptan treatment and drug holiday in patients with SIADH [abstract]. J Am Soc Nephrol. 2008;19(abstracts issue):588A
  37. Baylis PH. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol. 2003;35(11):1495–1499
  38. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26(1):53–77

 Originally published online as doi:10.1053/j.ajkd.2010.01.013 on June 10, 2010.

PII: S0272-6386(10)00478-6

doi: 10.1053/j.ajkd.2010.01.013

American Journal of Kidney Diseases
Volume 56, Issue 2 , Pages 325-337 , August 2010

Article Tools

* Image Usage & Resolution